10 indications for bevacizumab, usage and dosage, we summarized!

1.
Domestic medical insurance indications: metastatic colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma and recurrent glioblastoma
.

• Bevacizumab combined with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer;
  
• Dosage: In combination with chemotherapy regimen, 5mg/kg body weight, once every two weeks (5 mg/kg/q2w) or 7.
  5mg/kg body weight, once every 3 weeks (7.
  5mg/kg/q3w);
  
• Note: Continue until disease progression or intolerable toxicity
  .
  

• Bevacizumab plus platinum-based chemotherapy for first-line treatment of unresectable advanced, metastatic, or recurrent non-squamous NSCLC;

  
  

• Dosage: The recommended dose of bevacizumab is 15mg/kg body weight, administered once every 3 weeks (15 mg/kg/q3w);

  
  

• Note: Bevacizumab in combination with platinum-based chemotherapy for up to 6 cycles, followed by bevacizumab monotherapy until disease progression or intolerable toxicity
  .
  

• Dosage: The recommended dose of bevacizumab intravenous infusion is 10mg/kg body weight, administered once every two weeks (10mg/kg/q2w);
  
• Note: Continue until disease progression or intolerable toxicity
  .
  

• Dosage: After combining 1200mg with atezolizumab, intravenous infusion of bevacizumab 15 mg/kg, Q3W; After sindilimab 200 mg, intravenous infusion of bevacizumab 15 mg/kg, Q3W;
  
• Note: Continue until disease progression or intolerable toxicity
  .
  

2.
Domestic indications: including the four major medical insurance indications and recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer, refractory, recurrent or metastatic cervical cancer
.

• Dosage: Combined with "paclitaxel + cisplatin" or "paclitaxel + topotecan" regimen, the recommended dose is 15 mg/kg, Q3W;
  
• Note: Continue until disease progression or intolerable toxicity
  .
  

• Dosage: stage III/IV disease after initial surgical resection: the recommended dose of bevacizumab is 15 mg/kg once, once every 3 weeks (15mg/kg/q3w), combined with "paclitaxel + carboplatin" chemotherapy regimen for up to 6 cycles, followed by bevacizumab 15mg/kg/q3w alone;
  
• The total medication time of the drug is up to 22 cycles or continuous medication until disease progression, whichever occurs first;

3.
In addition to the indications described above, bevacizumab can also be used in metastatic renal cancer, advanced metastatic breast cancer, radiation brain injury, pleural effusion, and abdominal effusion
.

• in combination with α-interferon, or PD-1 monoclonal antibody for metastatic renal cancer;
  
• Dosage: treatment biweekly regimen: 10mg/kg; 3-week regimen: 7.
  5 mg/kg
  .
  

• in combination with paclitaxel or capecitabine for the treatment of metastatic breast cancer;
  
• Dosage: biweekly regimen: 10mg/kg; 3-week regimen: 15 mg/kg
  .
  

• Dosage: The recommended dose of bevacizumab is 5mg/kg, once every 2 weeks (5mg/kg/q2w), a total of 4 courses; Or bevacizumab 7.
  5mg/kg intravenous drip once, once every 3 weeks, according to the condition of 2~4 courses
  of treatment.
  
  
• It is not suitable for radiation brain injury lesions with bleeding and cystic changes, and should be used with caution in patients with a history of arterial thromboembolism or high risk
  .
  

• The addition of bevacizumab thoraucal/peritoneal perfusion to systemic chemotherapy can significantly improve control rates
  
• Dosage: The recommended dose is 300mg fixed dose, once every 2 weeks
  .
  

4.
Special dosage instructions

• Children and adolescents: the safety and efficacy of bevacizumab in children and adolescents is unclear
  .
  However, there are reports of osteonecrosis in other parts other than jaw osteonecrosis in people under 18 years of age using this drug, and this drug is not approved for people under 18 years old;
  
• Elderly: dose adjustment
  is not required when applied in elderly people (65 years and older).
  

5.
Management of common adverse reactions of bevacizumab